How to Prevent Endometrial Thickening in Patients on BHRT
All women with an intact uterus taking bioidentical hormone replacement therapy (BHRT) containing estrogen must receive concurrent progestogen therapy for at least 12 days per month to prevent endometrial hyperplasia and cancer. 1
The Critical Principle: Never Use Unopposed Estrogen
The evidence is unequivocal—unopposed estrogen dramatically increases endometrial hyperplasia risk regardless of whether it's "bioidentical" or conventional:
- At 6 months: 5.4-fold increased risk 2
- At 24 months: 9.6-fold increased risk 2
- At 36 months: 15-fold increased risk, with 62% developing some form of hyperplasia 2
This applies equally to bioidentical formulations. Case reports document endometrial cancer in women using bioidentical HRT without adequate progestogen protection 3.
Specific Progestogen Regimens That Provide Protection
Continuous Combined Regimens (Preferred for Long-Term Use)
For daily administration alongside estrogen:
- Norethisterone acetate (NETA): Minimum 1 mg daily 4
- Medroxyprogesterone acetate (MPA): Minimum 1.5 mg daily 4
- Micronized progesterone: 100-200 mg daily 5
- Dydrogesterone: Studied doses in combination formulations 5
The continuous combined approach shows no increased hyperplasia risk compared to placebo 4 and actually reduced endometrial cancer risk over 13 years of follow-up 1.
Sequential Regimens (Monthly Cycles)
Progestogen must be given for at least 12-14 days per month 1. However, important caveats exist:
- After 6-10 years, sequential regimens may carry a 2-fold increased endometrial cancer risk, particularly in thin women 1
- Long-cycle regimens (progestogen every 3 months) show higher hyperplasia rates than monthly sequential therapy 2 and raise concerns about cancer risk 1
- During year 1, sequential regimens cause less irregular bleeding than continuous regimens, but this reverses in year 2 2
Alternative: Levonorgestrel IUD
The levonorgestrel intrauterine device appears highly effective at minimizing hyperplasia and cancer risk, especially in obese women 1, though it's not FDA-approved for this indication in the U.S. (used off-label).
Critical Monitoring Requirements
For women on BHRT with a uterus:
Document the specific progestogen regimen: Dose, duration, and schedule
Higher-risk situations requiring closer surveillance:
If unscheduled bleeding occurs: Endometrial assessment is mandatory regardless of regimen 6
Common Pitfalls to Avoid
The "bioidentical" marketing trap: The term "bioidentical" does not confer safety advantages. The same endometrial protection rules apply—estrogen without adequate progestogen causes hyperplasia whether the hormones are bioidentical or not 3.
Inadequate progestogen duration: Giving progestogen for fewer than 12 days monthly provides insufficient protection 1.
Long-cycle sequential therapy: Extending progestogen intervals to every 3 months significantly increases hyperplasia risk compared to monthly administration 2.
Assuming low-dose estrogen is safe alone: Even low-dose unopposed estrogen shows a 3% hyperplasia incidence versus 0% with placebo 2.
The Algorithm
Patient with uterus starting BHRT with estrogen
↓
MUST add progestogen
↓
Choose regimen:
├─ Continuous combined (preferred for long-term)
│ └─ NETA ≥1mg OR MPA ≥1.5mg OR micronized progesterone 100-200mg daily
│
├─ Sequential monthly
│ └─ Progestogen ≥12-14 days/month
│ └─ Consider switching to continuous after 5 years
│
└─ Consider levonorgestrel IUD (off-label in US)
└─ Especially if obeseBottom line: There is no safe way to give estrogen-containing BHRT to a woman with a uterus without concurrent progestogen protection. The specific formulation matters less than ensuring adequate progestogen exposure—either continuously or for sufficient days each month.